Plain-English translation of NCT06759064 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a combination of two medications — Sintilimab (an immune-boosting drug) and zoledronic acid (a bone-strengthening medication) — can safely and effectively reduce fluid buildup in the abdomen caused by stomach cancer when injected directly into the abdominal cavity. The study will first test what dose is safe, then measure how well the treatment works at controlling this fluid.
Stomach cancer patients often develop painful, harmful fluid accumulation in their abdomen that can make them very sick. Current treatments don't work well enough for many people, so researchers are testing whether this new combination injection delivered directly to the affected area might provide better relief.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication mixture directly into your abdomen on a treatment schedule determined by the study doctors. The trial has two phases: first, doctors will test different doses to find the safest amount, then they will enroll more patients to measure how well the treatment reduces your fluid buildup. You will have regular visits for monitoring, blood tests, and imaging scans to track your response to treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China